---
title: "iBio Updates Governance Deadlines for 2026 Annual Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293079519.md"
description: "iBio, Inc. has updated governance deadlines for its 2026 Annual Meeting of Stockholders scheduled for October 14, 2026. Key dates include August 1, 2026, for Rule 14a-8 shareholder proposals and August 15, 2026, for proxy solicitation notices. The company reset these deadlines as the meeting date falls more than 30 days before the anniversary of the 2025 meeting. Analyst ratings remain mixed, with a Buy rating at $5.00 target, while AI analysis cites weak financials despite positive clinical catalysts."
datetime: "2026-07-17T21:31:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293079519.md)
  - [en](https://longbridge.com/en/news/293079519.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293079519.md)
generator: "portal-rs"
---

# iBio Updates Governance Deadlines for 2026 Annual Meeting

Ibio ( (IBIO) ) has shared an update.

iBio, Inc. has scheduled its 2026 Annual Meeting of Stockholders for October 14, 2026, with a record date of September 1, 2026 for determining shareholders entitled to vote. The time and location of the meeting will be provided in the company’s definitive proxy statement to be filed with regulators.

iBio has reset key governance deadlines because the 2026 meeting date will occur more than 30 days before the anniversary of the 2025 meeting. Shareholder proposals seeking inclusion in the proxy under Rule 14a-8 must be received by August 1, 2026, other proposals for presentation at the meeting must arrive by July 27, 2026, and notices related to soliciting proxies for alternative director nominees under universal proxy rules are due by August 15, 2026.

The most recent analyst rating on (IBIO) stock is a Buy  
 with a $5.00 price target.  
 To see the full list of analyst forecasts on Ibio stock,  
 see the IBIO Stock Forecast page. 

**Spark’s Take on IBIO Stock**

According to Spark, TipRanks’ AI Analyst, IBIO is a Neutral.

The score is held down primarily by very weak financial performance (minimal revenue, large losses, and ongoing free-cash-flow burn), which raises financing/dilution risk despite low leverage. Technicals are neutral-to-mixed with only modest near-term improvement and still-below longer-term trend levels. Positive corporate events (clinical trial start and encouraging preclinical data) provide upside catalysts but are not yet reflected in operating profitability.

To see Spark’s full report on IBIO stock,  
 click here. 

**More about Ibio**

iBio, Inc. is a U.S. biotechnology company whose operations are governed by standard public-company practices, including annual stockholder meetings and proxy processes that shape corporate governance and investor participation.

**Average Trading Volume:** 995,941

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $67.07M

Find detailed analytics on IBIO stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md)

## Related News & Research

- [iBio FY26 net loss widens to $33.04 million; revenue drops to $100,000](https://longbridge.com/en/news/297313027.md)
- [iBio announces annual shareholder meeting](https://longbridge.com/en/news/298071487.md)
- [Sherwin-Williams announces Q3 2026 dividend of R$ 0.28 per unit](https://longbridge.com/en/news/299050724.md)
- [LOG Commercial Properties publishes financial calendar update for 2026](https://longbridge.com/en/news/298951880.md)
- [Ecosuntek adds Q3 KPI update to 2026 corporate events calendar](https://longbridge.com/en/news/298712114.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**